Omni Bio Pharmaceutical to Present at Accredited Members Fall 2009 Micro Cap / Small Cap Investment Conference

DENVER, CO--(Marketwire - September 22, 2009) - Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) today announced that its executive management team will present at the Accredited Members Fall 2009 Micro Cap / Small Cap Investment Conference, which is being held at the Broadmoor Hotel Resort in Colorado Springs, CO, on September 28-29, 2009. Presenting on behalf of Omni Bio are Dr. Charles Dinarello, acting chief executive officer; Dr. Leland Shapiro, principal scientific investigator; and Edward Larkin, chief operating officer. The Company's presentation, which is scheduled for 3:30 p.m. MT on September 28, 2009, will include an update on current company developments. A copy of the slides used in the presentation will be filed with the Securities and Exchange Commission as an exhibit to a Form 8-K prior to the presentation.

About Omni Bio Pharmaceutical, Inc.

Omni is the licensee of issued and pending patents from the University of Colorado Denver. Omni has been advancing broad-spectrum therapeutics targeting bacterial and viral diseases, biohazards, diabetes, and transplant rejection since February 2006. The Company's core technology is based on novel discoveries made at the University of Colorado involving therapeutic agents already approved for use in humans.

Safe Harbor Statement

Certain statements in this press release and in the referenced presentation are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "target," and similar terms and phrases, including references to assumptions, to identify forward-looking statements. The forward-looking statements in this press release and in the presentation are based on information available to us as of the date any such statements are made and we assume no obligation to update these forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These risks and uncertainties include, but are not limited to, the following: our lack of revenue, our operating losses, our need for additional funding to continue operations, our ability to successfully commercialize our products, our limited experience in developing and commercializing products, the uncertainty and expense of clinical trials, our ability to adequately protect our intellectual property, the uncertainty and expense of government regulations, our limited product marketing capabilities and other risk factors described from time to time in our reports filed with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q all of which are available at www.sec.gov.